In addition, SSE manages a spectrum of signals in tumor cells such as AKT, glycogen synthase kinase 3 beta (GSK3β)/β-catenin, extracellular-signal-regulated kinase (ERK), and phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and because of these effects, SSE is a potential novel chemotherapy drug for cancer (Ren et al., 2009; Luo et al., 2013; Gong and Li, 2016; Kim et al., 2020). This evidence concerns the gene AKT1 and neoplasm.